The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...